Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 49
Semaglutide and body anxiety explained
Semaglutide users often report new health anxieties about muscle loss and nutrition. Here is what the research actually shows and what remains unknown.
Semaglutide bloating and nausea: trial data
Nausea, bloating and diarrhoea top the side-effect list for semaglutide. Here is what the STEP trial data says about how common they are and why.
What semaglutide does to daily life in MASH
A new ESSENCE analysis puts a number on how people with MASH feel on semaglutide: a small EQ-5D utility gain, and why payers will care about it.
Semaglutide and reward: what research shows
GLP-1 receptors sit inside the brain's dopamine reward circuit. Early trials suggest semaglutide may reduce craving well beyond food.
Stapled semaglutide variants, explained
A new chemistry paper built stapled variants of a semaglutide fragment that last longer in serum; here is what that does and does not show.
Surgery vs semaglutide for heart outcomes
A large real-world study compared semaglutide with bariatric surgery on heart outcomes in obesity. Here is what it found and what it cannot prove.
How semaglutide produces weight loss
Semaglutide works mainly in the brain, suppressing appetite via GLP-1 signalling. Here is what the STEP trials found and what stops when the drug stops.
Tirzepatide in youth: first real-world data
A study of 74 youth prescribed tirzepatide at three clinics found lower blood sugar and BMI. What can the first real-world numbers actually show?
Do other diabetes drugs stop on a GLP-1?
In 3,660 adults starting a GLP-1 or tirzepatide, the count of other glucose-lowering drugs fell for 17.2% of patients and rose for 44.0%.
GLP-1 drugs: how background therapy shifts
A 3,660-patient Polish study found 44% of patients on new incretin-class drugs had more background agents added, 39% saw no change, and 17% had agents removed.
Semaglutide and MASH: what ESSENCE found
Semaglutide has a licensed indication for MASH, the inflamed form of fatty liver disease. Here is what the ESSENCE trial showed, and what it has not.
STEP 12: semaglutide 2.4 mg, Chinese adults
The STEP 12 phase 3b trial tested once-weekly semaglutide 2.4 mg in 242 Chinese adults using Asia-Pacific BMI thresholds. Here is what the data showed.